Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 1/2000

01-12-2000 | Original Research Article

Comparison of the Systemic Availability of Fluticasone Propionate in Healthy Volunteers and Patients with Asthma

Authors: Dr Peter T. Daley-Yates, Julien Tournant, Robert L. Kunka

Published in: Clinical Pharmacokinetics | Special Issue 1/2000

Login to get access

Abstract

Objectives

The aim of this analysis was to compare the systemic exposure to inhaled fluticasone propionate (FP) after administration of either single or repeated dose regimens via dry powder and metered-dose inhalers in patients with asthma and healthy volunteers.

Background

The pharmacokinetics of FP, a topically active glucocorticoid administered by inhalation for the treatment of asthma and rhinitis, are well characterised in healthy volunteers. As asthma is characterised by pathophysiological changes in the lung, it may be inappropriate to use data from studies in healthy volunteers to predict the deposition and absorption of FP in patients with asthma.

Methods and results

Pooled data from 13 pharmacokinetic studies showed that the systemic availability of FP (measured as area under the plasma FP concentration-time curve) after single or multiple administration by inhalation was 2 to 3 times lower in patients with asthma than in healthy volunteers. This observation correlated well with the systemic effects of FP in the 2 groups. Reduction in 24-hour urinary cortisol excretion after inhalation of FP (determined in 9 of the studies) was greater in healthy volunteers than in patients with asthma. The hypothalamic-pituitary-adrenal axis suppression caused by systemic exposure to FP in adults with asthma is therefore substantially less than that in healthy volunteers.

Conclusion

Differences in the deposition of FP in the lungs of patients with asthma, probably caused by obstructed inspiratory airflow, may explain this observation.
Literature
1.
Holliday SM, Faulds D, Sorkin EM. Inhaled fluticasone propionate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma. Drugs 1994; 47: 318–31.PubMedCrossRef
2.
Wiseman LR, Benfield P. Intranasal fluticasone propionate: a reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis. Drugs 1997; 53: 885–907.PubMedCrossRef
3.
Falcoz C, Mackie AE, McDowall J, et al. Oral bioavailability of fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1996; 41: 459P–60P.
4.
Thorsson L, Dahlström K, Edsbäcker S, et al. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1997; 43: 155–61.PubMedCrossRef
5.
Mackie AE, McDowall JE, Ventresca P, et al. Systemic exposure to fluticasone propionate administered via metered-dose in- haler containing chlorofluorocarbon or hydrofluoroalkane propellant. Clin Phannacokinet 2000; 39 Suppl. 1: 17–22.CrossRef
6.
Mackie AE, McDowall JE, Falcoz C, et al. Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler® and Diskus® powder devices in healthy volunteers. Clin Pharma-cokinet 2000; 39 Suppl. 1: 23–30.CrossRef
7.
Mackie AE, Bye A. The relationship between systemic exposure to fluticasone propionate and cortisol reduction in healthy male volunteers. Clin Pharmacokinet 2000; 39 Suppl. 1:47–54.PubMedCrossRef
8.
Falcoz C, Mackie AE, Horton J, et al. Pharmacokinetics of fluticasone propionate inhaled from the Diskhaler® and the Diskus® powder devices in asthmatic patients. Br J Clin Pharmacol 1997; 43: 541P.
9.
Wixon C, Bogolubov M, Johnson L, et al. A multicentre, randomized, double-blind, double-dummy parallel-group comparison of the salmeterol/fluticasone combination product (50/500mcg strength) BD via one Diskus inhaler with salmeterol 50mcg BD via one Diskus inhaler and fluticasone propionate 500mcg BD via another Diskus inhaler and with fluticasone propionate 500mcg BD via one Diskus inhaler in adolescents and adults with reversible airways obstruction. Greenford, Middlesex, UK: Glaxo Wellcome, 1998 Apr 1. Study No.: SFCB3019.
10.
Kunka RL, Huffman C. The long term safety of fluticasone propionate inhalation aerosol 100mcg bid and 500mcg bid versus placebo bid in adult subjects with moderate asthma. Greenford, Middlesex, UK: Glaxo Wellcome, 1998 Jul 7. Study No.: FLTA3001.
11.
Mackie AE, Falcoz C, McDowall JE, et al. Pharmacokinetics of fluticasone propionate inhaled from the Diskhaler® and the Diskus® powder devices in healthy subjects. Br J Clin Pharmacol 1997; 43: 540P.
12.
Man CY, Falcoz C, Smith J. Safety, tolerability, pharmacokinetics and systemic pharmacodynamic effects of fluticasone propionate in the salmeterol/fluticasone propionate Diskus inhaler. Greenford, Middlesex, UK: Glaxo Wellcome, 1995 Oct 9. Study No.: SFCB1002.
13.
Kirby SM, Dallow N, Daley-Yates PT. Systemic pharmacodynamic effects and pharmacokinetics of salmeterol and fluticasone propionate when given together from a single or two separate Diskus inhalers. Greenford, Middlesex, UK: Glaxo Wellcome, 1998 Mar 19. Study No.: SFCB1005.
14.
Mackie AE, Moss JA. The bioavailability of fluticasone propionate from a CFC metered dose inhaler. Greenford, Middlesex, UK: Glaxo Wellcome, 1994 May 17. Study No.: C92–079.
15.
Kunka RL, Squassante L, Smith SM, et al. Dose proportionality of fluticasone propionate from 50, 125 and 250mcg HFA inhalers and comparability with 125 and 250mcg CFC inhalers. Greenford, Middlesex, UK: Glaxo Wellcome, 1998 Aug 31. Study No.: FLTB1020.
16.
Kirby SM, Milleri S, Squassante L, et al. The systemic pharmacodynamic effects and pharmacokinetics of salmeterol and fluticasone propionate when given alone and in combination, after repeat dosing from Diskus inhalers. Greenford, Middlesex, UK: Glaxo Wellcome, 1998 Feb 10. Study No.: SFCB1004.
17.
Brutsche MH, Carlen Brutsche I, Munawar M, et al. Pharmacokinetics and systemic effects of inhaled fluticasone propionate are different in asthmatics and normal volunteers [abstract]. Eur Respir J 1999; 14 Suppl. 30: 345s.
18.
Falcoz C, Horton J, Mackie AE, et al. Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler® and Diskus® powder devices in patients with mild-to-moderate asthma. Clin Pharmacokinet 2000; 39 Suppl. 1: 31–37.PubMedCrossRef
19.
Mackie AE, Ventresca GP, Fuller RW, et al. Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1996; 41: 539–42.PubMedCrossRef
20.
Rowland M, Tozer TN, editors. Clinical pharmacokinetics: concepts and applications. 3rd ed. Philadelphia: Williams & Wilkins, 1995.
21.
Bain BM, Harrison G, Jenkins KD, et al. A sensitive radioim-munoassay, incorporating solid-phase extraction, for fluticasone 17-propionate in plasma. J Pharm Biomed Anal 1993; 11: 557–61.PubMedCrossRef
22.
Jones AE, Callejas S, Sadra P, et al. The determination of drugs for the treatment of asthma in plasma by automated solid phase extraction and LC-MS. Proceedings of the 45th ASMS Conference on Mass Spectrometry and Allied Topics; 1997 Jun 1–5; Palm Springs, CA: 560.
23.
Falcoz C, Oliver R, McDowall JE, et al. Bioavailability of orally administered micronised fluticasone propionate. Clin Pharmacokinet 2000; 39 Suppl. 1: 9–15.PubMedCrossRef
24.
Melchor R, Biddiscombe MF, Mak VHF, et al. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax 1993; 48: 506–11.PubMedCrossRef
25.
Lipworth BJ, Clark DJ. Effects of airway calibre on lung delivery of nebulised salbutamol. Thorax 1997; 52: 1036–9.PubMedCrossRef
Metadata
Title
Comparison of the Systemic Availability of Fluticasone Propionate in Healthy Volunteers and Patients with Asthma
Authors
Dr Peter T. Daley-Yates
Julien Tournant
Robert L. Kunka
Publication date
01-12-2000
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue Special Issue 1/2000
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.2165/00003088-200039001-00006

Other articles of this Special Issue 1/2000

Clinical Pharmacokinetics 1/2000 Go to the issue

Original Research Article

Pharmacokinetics of Fluticasone Propionate Inhaled via the Diskhaler® and Diskus® Powder Devices in Patients with Mild-to-Moderate Asthma

Original Research Article

Pharmacokinetics of Fluticasone Propionate Inhaled via the Diskhaler® and Diskus® Powder Devices in Healthy Volunteers

Original Research Article

The Relationship between Systemic Exposure to Fluticasone Propionate and Cortisol Reduction in Healthy Male Volunteers

Original Research Article

Bioavailability of Orally Administered Micronised Fluticasone Propionate

Original Research Article

Absorption Kinetics after Inhalation of Fluticasone Propionate via the Diskhaler®, Diskus® and Metered-Dose Inhaler in Healthy Volunteers

Original Research Article

Systemic Exposure to Fluticasone Propionate Administered via Metered-Dose Inhaler Containing Chlorofluorocarbon or Hydrofluoroalkane Propellant